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Abstract
Background Neurofibromatosis type 1 (NF1) is a multi‐organ disease caused by mutations in neurofibromin 1 (NF1).
Amongst other features, NF1 patients frequently show reduced muscle mass and strength, impairing patients’ mobility and
increasing the risk of fall. The role of Nf1 in muscle and the cause for the NF1‐associated myopathy are mostly unknown.
Methods To dissect the function of Nf1 in muscle, we created muscle‐specific knockout mouse models for NF1, inactivating
Nf1 in the prenatal myogenic lineage either under the Lbx1 promoter or under the Myf5 promoter. Mice were analysed during
prenatal and postnatal myogenesis and muscle growth.
Results Nf1Lbx1 and Nf1Myf5 animals showed only mild defects in prenatal myogenesis. Nf1Lbx1 animals were perinatally
lethal, while Nf1Myf5 animals survived only up to approximately 25 weeks. A comprehensive phenotypic characterization of
Nf1Myf5 animals showed decreased postnatal growth, reduced muscle size, and fast fibre atrophy. Proteome and tran-
scriptome analyses of muscle tissue indicated decreased protein synthesis and increased proteasomal degradation, and de-
creased glycolytic and increased oxidative activity in muscle tissue. High‐resolution respirometry confirmed enhanced
oxidative metabolism in Nf1Myf5 muscles, which was concomitant to a fibre type shift from type 2B to type 2A and type 1.
Moreover, Nf1Myf5 muscles showed hallmarks of decreased activation of mTORC1 and increased expression of atrogenes.
Remarkably, loss of Nf1 promoted a robust activation of AMPK with a gene expression profile indicative of increased fatty acid
catabolism. Additionally, we observed a strong induction of genes encoding catabolic cytokines in muscle Nf1Myf5 animals, in
line with a drastic reduction of white, but not brown adipose tissue.
Conclusions Our results demonstrate a cell autonomous role for Nf1 in myogenic cells during postnatal muscle growth re-
quired for metabolic and proteostatic homeostasis. Furthermore, Nf1 deficiency in muscle drives cross‐tissue communication
and mobilization of lipid reserves.
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Introduction
Neurofibromatosis type 1 (NF1) is a multi‐organ disease
caused by mutations in the NF1 gene. NF1 encodes a Ras‐
GTPase‐activating protein, neurofibromin 1, which negatively
regulates Ras signalling, mainly feeding into the MAPK path-
way, specifically Mek1/2–Erk1/2 signalling, depending on
the cell type. In contrast, other pathways were shown to be
activated, such as cAMP in Schwann cells, or PI3Kinase/AKT
in astrocytes and malignant peripheral nerve sheath
tumours.1 The musculoskeletal system is often affected in
NF1 patients, with scoliosis, long bone dysplasia, and osteo-
porosis being a main cause of considerable morbidity.2 Fur-
thermore, pronounced reduction of muscle size and muscle
weakness has been reported in NF1 patients3–8 and has also
been described as general feature in RASopathies, that is, dis-
ease traits with mutations in RAS pathway components.9,10
However, the cause of muscle weakness is unknown.
Skeletal muscles consist of syncytial multinucleated
myofibres that produce force based on the activity of con-
tractile proteins. During postnatal growth, myofibres continu-
ously increase their size by myonuclear accretion and protein
synthesis, mainly components of the contractile machinery,
in a process termed hypertrophy.11,12 Myofibres are generally
classified into slow‐twitching type 1 and fast‐twitching type 2
fibres that differ in the expression of specific myosin heavy
chain isoforms as well as their metabolic profile. While
slow‐twitching fibres mainly rely on oxidative metabolism
based on carbohydrates and fatty acids, fast‐twitching fibres
are further divided into fast oxidative (type 2A) or fast glyco-
lytic (type 2B and 2X in mice, 2X in humans) fibres.13–15 My-
opathies affect the functionality of muscle fibres, by, for
example, perturbing the function of contractile proteins or
the integrity of the myofibre, or by changes in protein turn-
over leading to net protein loss and myofibre atrophy.
Thereby, fibre types can be differentially affected, for exam-
ple, in Duchenne muscular dystrophy or in age‐related
sarcopenia; predominantly, fast glycolytic fibres are most
prone to atrophy.15,16
During development, skeletal muscles of the trunk arise
from the somitic mesoderm. The muscles of the limbs instead
originate from the ventrolateral lip of the dermomyotome,
where cells detach and migrate into the limb buds, where
they invade the resident mesenchyme. There, cells start to in-
duce a cascade of so‐called myogenic regulatory factors
(Myf5, Myf6/Mrf4, MyoD, and myogenin) that consecutively
specify and consolidate myogenic commitment and differen-
tiation. Inactivation of Nf1 in limb mesenchyme during
development using Prx1Cre recapitulated the skeletal manifes-
tations of NF117,18 but also caused an early‐onset defect in
embryonal myogenesis,19 providing the first evidence for a di-
rect involvement of Nf1 in myogenesis. Postnatally, Nf1Prx1
mice recapitulated NF1 features as muscle weakness and
fibro‐fatty infiltration of muscle.19,20 However, in this model,
Nf1 is inactivated in the skeleton as well as in the accessory
tissues of muscles (tendons and connective tissue).19,21 Inac-
tivation of Nf1 in the myogenic lineage using MyoDCre re-
sulted in early postnatal lethality22 limiting the utility of this
model for postnatal analysis.
Here, we use Lbx1Cre and Myf5Cre to delete Nf1 in the myo-
genic lineage. Lbx1Cre leads to inactivation in early migrating
progenitors, while Myf5Cre leads to inactivation in committed
myoblasts. While Lbx1Cre‐mediated inactivation of Nf1 led to
perinatal lethality, inactivation of Nf1 via Myf5Cre provided vi-
able offspring and allowed postnatal analysis. We show that
loss of Nf1 in the myogenic lineage compromises postnatal
muscle growth resulting in severely reduced muscle size
caused by decreased mTORC1 signalling activity. Moreover,
Nf1‐deficient muscle shows a glycolytic‐to‐oxidative fibre
type shift concomitant to decreased carbohydrate but in-
creased lipid metabolism and attrition of white adipose tissue
(WAT). This demonstrates a cell autonomous requirement for
Nf1 in the myogenic lineage and provides a mechanistic ex-
planation for NF1‐associated muscle weakness.
Methods
Animals
Mouse lines used in this study were described before: Myf5-
Cre,23 Lbx1Cre,24 Nf1flox,25 and Rosa26mTmG.26 All animal proce-
dures conducted within this study have been approved by
the appropriate ethics committee and have therefore been
performed in accordance with the ethical standards laid
down in the 1964 Declaration of Helsinki and its later amend-
ments. Animal studies were conducted in accordance with
FELASA guidelines and were approved by the responsible au-
thority (Landesamt für Gesundheit und Soziales Berlin,
LAGeSo) under license numbers ZH120, G0346/13, and
G0176/19. Timed matings were set up, and mice were
sacrificed by cervical dislocation at indicated days of preg-
nancy; foetuses were sacrificed by decapitation.
Tissue processing and histology
Forelimbs and hindlimbs of mice were dissected, limbs from
the right side of the body were embedded in paraffin, and
limbs from the other side were snap‐frozen in liquid nitrogen,
followed by RNA, gDNA, or protein isolation. Adipose tissue
was taken for RNA isolation and paraffin embedding. Muscle
tissue was embedded with tragacanth (Sigma‐Aldrich
#G1128) on a cork plate into cold isopentane for 10 s; then
samples were transferred on dry ice and stored at 80°C. Ad-
ipose tissue was embedded with paraffin after using PFA fix-
ation and rounds of dehydration. Cryoembedded samples
were sectioned using a microtome (Microm HM355S) with a
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thickness of 10 μm. For immunostaining, slides were fixed
with methanol for 10 min at 20°C. Antigen retrieval was
used for Pax7 staining with antigen retrieval solution (2 mM
EDTA) for 10 min at 95°C water bath (Julabo). Slides were
blocked with blocking buffer (5% BSA in PBX) for 1 h at room
temperature. Primary antibodies were diluted with blocking
buffer and incubated overnight at 4°C. To remove primary an-
tibody, slides were washed four times 10 min each with PBX.
Secondary antibody was applied in PBX for 1 h at room tem-
perature followed by washing with PBX for four times. Slides
were mounted with Fluoromount‐G (Southern Biotech,
#0100‐01). Imaging was performed on a LSM700 confocal mi-
croscope (Zeiss) with ZEN imaging software (Zeiss). The pri-
mary antibodies and dilutions used were goat anti‐collagen
IV (Millipore AB769; 1:500), mouse anti‐MyHC type 1 (DSHB
BA‐D5; 1:500), mouse anti‐MyHC type 2A (DSHB SC‐71;
1:200), rabbit anti‐laminin (Sigma‐Aldrich L9393; 1:500),
mouse anti‐Pax7 (DSHB Pax7; 1:10), mouse anti‐myosin
heavy chain (Sigma‐Aldrich 05‐716; 1:1000), anti‐beta III tu-
bulin antibody (Sigma‐Aldrich AB9354; 1:500), and
anti‐perilipin A/B antibody (Sigma‐Aldrich p1873; 1:250). For
all the immunostaining analysis, three to five animals were
used for each genotype as indicated in the figure legends.
Paraffin embedding of adipose tissue from control (n = 3)
and Nf1Myf5 (n = 3) animals were used for haematoxylin and
eosin staining; slides were fixed with 4% PFA at room temper-
ature for 10 min and then incubated with haematoxylin (Carl
Roth 3816) for 1 min, followed by eosin (Sigma Aldrich
#15086‐94‐9) staining for 30 s. Slides were dehydrated by in-
cubation for 5 min each in 70% EtOH–80% EtOH–90% EtOH–
100% EtOH–xylene (Carl Roth #CN80). Slides were mounted
with Permount medium (Science Service E17986).
Oil Red O staining was performed with control (n = 3) and
Nf1Myf5 (n = 3) muscle sections from different development
stages; slides were rinsed with 60% isopropanol (Carl Roth
6752) for 10 min followed by incubation with Oil Red O
(Sigma Aldrich O0625) staining solution (0.5 g Oil Red O in
100 mL isopropanol) for 15 min. Then slides were rinsed with
60% isopropanol for 10 min and washed with PBS before
mounting and imaging.
Quantitative RT–PCR
Total RNA was isolated with RNeasy Micro Kit or RNeasy Mini
Kit (Qiagen). cDNA was synthesized using 1 μg of mRNA with
SuperScript™ III Reverse Transcriptase (Invitrogen 18080044),
Oligo(dT)20 Primer (Invitrogen 18418020), and RNaseOUT
Recombinant Ribonuclease Inhibitor (ThermoFisher Scientific
10777019) according to the protocol provided by the manu-
facturers. In brief, 1:10 cDNA dilution was used for each reac-
tion of quantitative RT–PCR analysis performed on an ABI
Prism HT 7900 real‐time PCR detection system (Applied
Biosystems) equipped with SDS software version 2.4
(ThermoFisher Scientific) using GoTaq qPCR Master Mix
(Promega) or SYBR Green qPCR Master Mix (Life Technolo-
gies). Beta‐actin was used to normalize the expression of
each gene. All primers used were purchased from Eurofins
Scientific and are listed in the Supporting Information, Table
S1. For all assays, samples from three to four animals per ge-
notype were used in three technical replicates.
RNA sequencing analysis
Total RNA was isolated from tibialis anterior (TA) muscles of
two p21 Myf5Cre;Nf1flox/+ and two p21 Myf5Cre;Nf1flox/flox an-
imals using RNeasy Micro Kit or RNeasy Mini Kit (Qiagen). Af-
ter initial quality control using Agilent Bioanalyzer,
sequencing libraries were prepared from 500 ng of total
RNA per sample following Roche’s ‘KAPA stranded mRNA
Seq’ library preparation protocol for single indexed Illumina
libraries: first, the polyA‐RNA fraction was enriched using
oligo‐dT‐probed paramagnetic beads. Enriched RNA was heat
fragmented and subjected to first‐strand synthesis using ran-
dom priming. The second strand was synthesized incorporat-
ing dUTP instead of dTTP to preserve strand information.
After A‐tailing Illumina sequencing compatible adapters were
ligated. Following bead‐based clean‐up steps, the libraries
were amplified using 11 cycles of PCR. Library quality and size
was checked with qBit, Agilent Bioanalyzer, and qPCR. Se-
quencing was carried out on an Illumina HiSeq 4000 system
in PE75bp mode yielding between 45 and 72 million frag-
ments per sample. Mapping was performed using STAR
2.4.2a software with mouse genome (mm9). Read counts
were generated with R Studio function Summarize Overlaps
and normalized to RPKM based on the number of uniquely
mapped reads. Differential expression analysis was per-
formed with DESeq2 using default settings. Genes with an ab-
solute fold change > 2 and adjusted P‐value < 0.01 were
assessed to be significantly differentially expressed. A table
of DESeq2 analysis can be found in the Supporting Informa-
tion, Data S1. Gene set enrichment analysis (GSEA) was per-
formed with the entire gene list using GSEA software 4.0.1
desktop (Broad Institute). KEGG and gene ontology (GO) en-
richment analysis was performed using the Signature Data-
base (MSigDB) and DAVID 6.8. RNA‐seq data have been
deposited in the Gene Expression Omnibus database under
the SuperSeries accession number GSE147605.
Immunoblotting
For protein isolation, tissue homogenization was performed
with a TissueLyser (Qiagen) with RIPA buffer (50 mM Tris–
HCl, pH 8.0; 150 mM NaCl; 1% NP‐40; 0.5% sodium
deoxycholate; 0.1% SDS). Protein concentration was mea-
sured with the Pierce BCA Protein Assay Kit (Thermo Fisher
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#23225). Protein concentration from all samples was adjusted
to 1.5 or 3 μg/μL. Total protein (30 μg) was separated with
SDS‐PAGE gels and transferred to PVDF membrane (GE
Healthcare). Membranes were blocked with 5% BSA in TBST
for 1 h at room temperature. Primary antibodies were diluted
in blocking buffer and applied overnight at 4°C. Antibodies
used were rabbit anti‐PPARG (Cell Signaling Technology
2443), rabbit anti‐phosphor (pThr172) AMPKa (Cell Signaling
Technology 2535), rabbit anti‐AMPKα (Cell Signaling Technol-
ogy 2532), mouse anti‐β‐actin (Cell Signaling Technology
58169), mouse anti‐β‐tubulin (Sigma‐Aldrich T8328), rabbit
anti‐phosphor (s235/236) S6 (Cell Signaling Technology
4858), mouse anti‐MyHC type 1 (DSHB BA‐D5), mouse
anti‐MyHC type 2B (DSHB BF‐F3), rabbit anti‐phosphor
(Ser473) AKT (Cell Signaling, #9271; 1:1000), rabbit
anti‐phospho (Ser1101) IRS‐1 (Cell Signaling, #2385; 1:1000),
and rabbit anti‐phospho (Ser636/639) IRS‐1 (Cell Signaling,
#2388; 1:1000). Secondary antibodies were applied for 1 h
at room temperature. Antibodies used were IgG (HRP conju-
gated) anti‐rabbit (Thermo Fisher; 1:1000) and IgG (HRP con-
jugated) anti‐mouse (Thermo Fisher; 1:1000). Images were
acquired using a Fusion FX spectra gel documentation system
(Vilber) with FUSION FX software. Blots images were analysed
with ImageJ grey value analysis tool. For quantification, sam-
ples from at least three animals per genotype were analysed
in at least three technical replicates.
Proteomics sample preparation
Three biological replicates of Nf1Myf5 and control (Nf1flox/+;
Myf5Cre and Nf1+/+;Myf5Cre) TA muscles from p21 mice were
used for proteome profiling. Proteomics sample preparation
was performed according to a published protocol with minor
modifications.27 In brief, about 10 mg frozen tissue per sam-
ple were homogenized under denaturing conditions with a
FastPrep (two times for 60 s, 4 m/s) in 1 mL of a buffer con-
taining 6 M guanidinium chloride (GdmCl), 5 mM tris(2‐
carboxyethyl)phosphine, 20 mM chloroacetamide, and
50 mM Tris–HCl pH 8.5. Lysates were boiled at 95°C for
15 min in a thermal shaker, followed by sonication for
15 min, and centrifuged at 15 000 g for 5 min. The superna-
tant was transferred into new protein low binding tubes
(Eppendorf, Germany). One hundred micrograms of protein
per sample were diluted to 1 M GdmCl by adding 10% aceto-
nitrile and 25 mM Tris, 8.5 pH, followed by a Lys‐C digestion
(1:50) at 37°C for 2 h. This was followed by another dilution
to 0.5 M GdmCl and a tryptic digestion (1:50) at 37°C over-
night. Subsequently, peptides were desalted with C18 col-
umns and reconstituted in 1% formic acid in water and
further separated into five fractions by strong cation ex-
change chromatography (SCX, 3M Purification, Meriden,
CT). Eluates were first dried in a SpeedVac, then dissolved
in 20 μL 5% acetonitrile and 2% formic acid in water, briefly
vortexed, and sonicated in a water bath for 30 s prior injec-
tion to nano‐LC–MS/MS. Five micrograms of each SCX frac-
tion and a non‐fractioned sample were used for proteome
profiling and analysed by MaxQuant (v1.5.3.30).
LC–MS/MS instrument settings for shotgun
proteome profiling with label‐free quantification
and data analysis
LC–MS/MS was carried out by nanoflow reverse phase liquid
chromatography (Dionex Ultimate 3000, Thermo Scientific)
coupled online to a Q‐Exactive HF Orbitrap mass spectrome-
ter (Thermo Scientific), as reported previously.28 Briefly, the
LC separation was performed using a PicoFrit analytical col-
umn (75 μm ID × 50 cm long, 15 μm Tip ID; New Objectives,
Woburn, MA) in‐house packed with 3 μm C18 resin (Reprosil‐
AQ Pur, Dr. Maisch, Ammerbuch, Germany). Peptides were
eluted using a gradient from 3.8 to 38% solvent B in solvent
A over 120 min at 266 nL/min flow rate. Solvent A was
0.1% formic acid, and solvent B was 79.9% acetonitrile, 20%
H2O, and 0.1% formic acid. Nanoelectrospray was generated
by applying 3.5 kV. A cycle of one full Fourier transformation
scan mass spectrum (300–1750 m/z, resolution of 60 000 at
m/z 200, automatic gain control target 1 × 106) was followed
by 12 data‐dependent MS/MS scans (resolution of 30 000,
automatic gain control target 5 × 105) with a normalized col-
lision energy of 25 eV. In order to avoid repeated sequencing
of the same peptides, a dynamic exclusion window of 30 s
was used. In addition, only peptide charge states between
two and eight were sequenced.
Raw MS data were processed with MaxQuant software
(v1.5.3.30) and searched against the mouse proteome data-
base UniProtKB (UP000000589) with 54 416 entries, released
in March 2016. Parameters of MaxQuant database searching
were a false discovery rate (FDR) of 0.01 for proteins and
peptides, a minimum peptide length of seven amino acids, a
first search mass tolerance for peptides of 20 ppm, and a
main search tolerance of 4.5 ppm. A maximum of two missed
cleavages was allowed for the tryptic digest. Cysteine carba-
midomethylation was set as fixed modification, while
N‐terminal acetylation and methionine oxidation were set
as variable modifications. The label‐free quantification algo-
rithm, implemented in MaxQuant, was used for data normal-
ization. The MaxQuant processed output files can be found in
the Supporting Information, Data S2, showing peptide and
protein identification, accession numbers, % sequence cover-
age of the protein, q‐values, and label‐free quantification in-
tensities. The mass spectrometry data have been
deposited to the ProteomeXchange Consortium (http://
proteomecentral.proteomexchange.org) via the PRIDE part-
ner repository29 with the dataset identifier PXD017958.
Statistical analysis was performed by a two‐sample t‐test
with Benjamini–Hochberg (FDR of 0.05) correction for
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multiple testing. Significantly regulated proteins between
Nf1Myf5 and controls were indicated in the Supporting Infor-
mation, Data S3, and were submitted to DAVID bioinformat-
ics 6.8 for functional annotation analysis. For comprehensive
proteome data analyses, GSEA (v2.2.3)30 was applied in order
to see if a priori defined sets of proteins show statistically sig-
nificant, concordant differences between Nf1Myf5 and con-
trols. GSEA standard settings were used, except that the
minimum size exclusion was set to 5 and KEGG v5.2 were
used as gene set databases. The cut‐off for significantly regu-
lated pathways was set to be ≤0.05 P‐value and ≤0.05 FDR.
High‐resolution respirometry
Extensor digitorum longus (EDL) and soleus muscles from
5 weeks control (n = 7) and Nf1Myf5 (n = 7) mice were used
in this experiment. Briefly, gently dissected muscles were
put into ice‐cold biopsy preservation medium (in mM: 2.77
CaK2EGTA, 7.23 K2EGTA, 20 imidazole, 20 taurine, 6.56MgCl2,
5.77 ATP, 3.95 phosphocreatine, 0.5 dithiothreitol, 50 K‐MES,
pH 7.1 at °C) followed by permeabilization with saponin
(50 μg/mL) in biopsy preservation medium at 4°C for
30 min. Fibres were washed with mitochondrial respiration
medium (MiR05, 110 mM sucrose, 60 mM K‐lactobionate,
0.5 mM EGTA, 3 mM MgCl2, 20 mM taurine, 10 mM KH2PO4,
20 mM HEPES, pH 7.1, and 0.1% fatty acid‐free BSA) at 4°C
for 10 min. All samples were kept on ice before analysis.
The basic principle of this method is to analyse the respira-
tory capacity at 37°C in a hyperoxygenated environment
using a multiple substrate‐uncoupler‐inhibitor titration
protocol.31 The following concentrations were used: 2 mM
malate + 5 mM pyruvate (LEAK respiration), 5 mM ADP
(OXPHOS capacity), 10 μM cytochrome c (integrity of outer
mt‐membrane), 10 mM glutamate (OXPHOS capacity),
10 mM succinate (OXPHOS capacity), 0.5 μM FCCP (ETS ca-
pacity, ETSCI&CII), 0.5 μM rotenone (ETS capacity, ETSCII),
and 2.5 μM antimycin A (residual oxygen consumption,
ROX) that were used with high‐resolution Oxygraph‐2k
(OROBOROS Instruments). DatLab software (OROBOROS IN-
STRUMENTS) was used for data acquisition and analysis. All
data were normalized to non‐mitochondrial residual oxygen
consumption (after complex I and III inhibition by adding ro-
tenone and antimycin A) and muscle fibre wet weight. Stu-
dent’s t‐test (unpaired, two‐tailed) was used to determine
differences between genotypes for each respiratory state.
Whole mount in situ hybridization
Embryos at the stage E14.5 were dissected and fixed over-
night in 4% PFA/PBS. Embryos were washed twice in PBST
for 30 min on ice and dehydrated through 25%, 50%, and
75% methanol in PBST (DEPC‐H2O), twice in 100% methanol
for 10 min, and were stored in methanol at 20°C. Embryos
were rehydrated passing through 75%, 50%, and 25% metha-
nol in PBST (DEPC‐H2O) and washed twice with 1× PBS (DEPC‐
H2O) on ice. Afterwards, embryos were bleached with 6% hy-
drogen peroxide in PBST for 1 h on ice. After washing three
times for 10min in PBST, embryos were treated with protein-
ase K (20 μg/mL, Roche) at room temperature for 12 min.
Embryos were washed with PBST, PBST/glycine, and RIPA
buffer for 10 min each and fixed with 4% PFA/0.2% glutaral-
dehyde for 20 min followed by washing with PBST,
PBST/hybridization buffer, and hybridization buffer (50%
formamide, 5× SSC pH 4.5, 1% SDS and 0.1% Tween‐20,
0.1 mg/mL tRNA, and 0.05 mg/mL heparin). Embryos were
pre‐hybridized in hybridization solution at 65°C for 3 h,
followed by incubation in hybridization buffer containing a
digoxygenin‐labelled MyoD mRNA probe at 65°C overnight.
Embryos were washed with hybridization buffer at 65°C for
30 min, followed by digestion with RNase A at 37°C for
30 min. Embryos were washed with formamide buffer (50%
formamide, 2× SSC pH 4.5, 0.1% Tween‐20 in DEPC‐water)
at 65°C for 30min, followed by two washing steps with MABT
for 15 min each. Embryos were incubated in blocking solution
(2% foetal calf serum, 2 mg/mL bovine serum albumin dis-
solved in TBST) for 1 h and subsequently incubated with
anti‐DIG‐Fab antibody coupled to alkaline phosphatase
(Roche, 11093274910) in blocking solution (1 in 5000) at 4°
C overnight. Embryos were washed with PBST/tetramisol
overnight. Embryos were equilibrated to ALP buffer for three
times, 20 min each, and then transferred to BM purple AP
substrate (Roche, 11442074001). For signal conservation,
the embryos were washed three times with ALP buffer and
then fixed in 4% PFA/PBS. Imaging was performed using a
Zeiss Stereo Discovery V12 and the AxioVision 4.6 software
(Zeiss). Measurement and quantification of MyoD+ stained
area were performed on three embryos for each genotype
with the Autmess function of AxioVision 4.6.
Results
Conditional inactivation of Nf1 in myogenic
progenitors causes reduction of postnatal muscle
growth
To specifically inactivate Nf1 in the myogenic lineage, we
used the Lbx1Cre24 and Myf5Cre23 lines, targeting migrating
and early committed myogenic progenitors, respectively.
Both lines were reanalysed for their specific activity in the
myogenic lineage (Supporting Information, Figure S1A and
S1B). In the limbs, Lbx1Cre and Myf5Cre were highly specific
to the myogenic lineage and did not cause reporter recombi-
nation in, for example, neural cells, connective tissue, or car-
tilage. The Myf5Cre line showed minimal off‐target activity in
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FIGURE 1 Muscle‐specific inactivation of Nf1 causes reduced postnatal muscle growth. (A) Forelimb cross sections of control, Nf1Lbx1, and Nf1Myf5
E18.5 foetuses stained for pan‐MyHC. Triceps brachii (TB) muscle is indicated; squared region is shown as magnification in inserts. (B) Quantification




animals. (C) Quantification of myotube diameter in TB muscles of E18.5 controls,
Nf1Lbx1, and Nf1Myf5 animals. (D) Quantification of number of centrally located nuclei in TB muscles of E18.5 controls, Nf1Lbx1, and Nf1Myf5 animals. (B–
D: n = 3 animals per genotype). (E) Control and Nf1
Myf5
mice at 12 weeks of age. (F) Weight curve of control (black) and Nf1
Myf5
(red) animals during
postnatal life starting at postnatal day 7 (n = 4 animals per genotype; P < 0.001; two‐way analysis of variance with Bonferroni post‐test). (G) Dissected
gastrocnemius (Gas) and tibialis anterior (TA) muscles of control and Nf1Myf5 animals at 7 weeks of age. Quantification is shown right (n = 3 animals per
genotype). (H) RT‐qPCR analysis of Nf1 deletion efficacy in E18.5 or p21 muscle tissue from control vs. Nf1Myf5 mice (n = 3 animals per genotype). (I)
RNA‐Seq tracks showing coverage of Nf1 exons 40 and 41 in control and Nf1Myf5 mice. Quantification is shown right (RPKM, reads per kilobase million).
(J) Appearance of 22‐week‐old control and Nf1
Myf5
animals. Right: TB and TA CSA of E18.5, p21, and 22‐week‐old Nf1
Myf5
animals are depicted relative
to controls, which was set as 100% (horizontal line) (n = 3 animals per genotype). Error bars represent standard error of means. P‐value was calculated
by two‐sided unpaired t‐test except for (F).
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dorsal root ganglia, as described previously,23 but no recom-
bination was detected in limb neurons (Supporting Informa-
tion, Figure S1A and S1B). Unlike inactivation of Nf1 in limb
mesenchyme using Prx1Cre,19 inactivation in the myogenic lin-
eage did not cause a marked defect in early myogenesis at
embryonal day (E) 14.5 (Supporting Information, Figure
S2A). In late foetal development (E18.5) in both lines,
myofibre cross‐sectional areas were unaltered, while
myofibre diameters tended to be decreased, and numbers
of central myonuclei were increased (Figure 1A–1D), indicat-
ing a slight developmental delay. Newborn Lbx1Cre;Nf1flox/flox
mice were smaller, exhibited cyanosis and lack of feeding,
and died perinatally. Myf5Cre;Nf1flox/flox mice were born at
normal Mendelian ratios at normal size and were used for
further analysis. Myf5Cre;Nf1flox/flox mice are further on
termed ‘Nf1Myf5’. Myf5Cre;Nf1flox/+ mice were indistinguish-
able from Nf1+/+ mice and had equal Nf1 mRNA expression
levels (Supporting Information, Figure S2B) and were there-
fore used as controls unless otherwise noted. Postnatally,
Nf1Myf5 mice showed a marked growth retardation and
weight reduction (Figure 1E and 1F). Dissection of individual
muscles (gastrocnemius and tibialis anterior, TA) showed sig-
nificantly decreased muscle size (Figure 1G) compared with
control littermates at 7 weeks of age. Efficacy of Nf1 deletion
was controlled in E18 and p21 muscle tissue (Figure 1H and
1I). Note that, although the Myf5Cre allele is a loss of function,
Myf5 mRNA expression in whole muscle tissue both during
development (E18.5) and at p21 was indistinguishable be-
tween Myf5+/+ and Myf5Cre/+ mice (Supporting Information,
Figure S2C), indicating compensation by the intact allele.
The reduction in muscle size was observed throughout
lifespan (Figure 1J), which for Nf1Myf5 mice consistently was
approximately 20–25 weeks. Together, this suggests a defect
in postnatal muscle growth.
Fast fibre atrophy of Nf1Myf5 muscles
We next analysed muscles of young mice amidst the most in-
tense phase of muscle growth, at 3 weeks of age (p21) by
FIGURE 2 Muscle‐specific inactivation of Nf1 causes fast fibre atrophy. (A) Cross sections of forelimb and hindlimb of control and Nf1Myf5 animals.
Staining: collagen IV (green), DAPI (blue). EDL, extensor digitorum longus; Fi, fibula; Hu, humerus; TA, tibialis anterior; TB, triceps brachii; Ti, Tibia.
(B) Quantification of the cross‐sectional area of muscles indicated [n = 4 (controls), n = 5 (Nf1Myf5)]. (C) Quantification of minimum Feret’s diameter
of individual muscle fibres on tissue cross sections of muscles indicated [n = 4 (controls), n = 5 (Nf1Myf5)]. (D) Distribution of myofibre diameter in con-
trol and Nf1
Myf5 animals [n = 4 (controls), n = 5 (Nf1Myf5)]
. (E) Cross section of TA muscles of control and Nf1
Myf5
animals. Staining: myosin heavy chain type 1
(red), laminin (green), DAPI (blue). Quantification of diameters of type 1 vs. type 2myofibres is shown right [n = 3 (controls), n = 4 (Nf1Myf5)]. Error bars
represent standard error of means. P‐value was calculated by two‐sided unpaired t‐test.
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histology. Muscles in forelimb and hindlimb [triceps brachii
(TB), tibialis anterior (TA), and extensor digitorum longus
(EDL)] showed reduced cross‐sectional area (Figure 2A and
2B). Centrally located myonuclei were not observed in mus-
cles of p21 or 12‐week‐old Nf1Myf5 mice (not shown).
Myofibre numbers were not significantly altered in all three
muscles (Supporting Information, Figure S2D). Conversely,
myofibre diameter was reduced in TB, TA, and EDL of Nf1Myf5
mice (Figure 2C). This was confirmed by binning fibre diame-
ters of TB, TA, and EDL into discrete size windows, demon-
strating global shift towards smaller fibres in Nf1Myf5 mice
(Figure 2D). Staining for type 1 fibres (MyHC‐1+) revealed a
predominant size reduction of type 2 muscle fibres (Figure
2E). We conclude that Nf1Myf5 mice show impaired postnatal
myofibre growth and persistent fast myofibre atrophy.
Proteome and transcriptome analyses of Nf1Myf5
muscles
To assess global changes in Nf1‐deficient muscle tissue, we
performed proteome as well as transcriptome analysis of
whole TA muscles at p21. Note that for the proteome analysis
we used both Myf5Wt;Nf1flox/+ and Myf5Cre;Nf1flox/+ muscle
tissues as controls. Principal component analysis showed that
both control genotypes were grouped together, while
Nf1Myf5 samples were grouped separately (Supporting
Information, Figure S3A). This demonstrates that, at least
on the proteome level, influence of the Myf5Cre allele
(i.e. haploinsufficiency for Myf5), as well as Nf1
haploinsufficiency, can be neglected. Proteome analysis of
p21 TA muscle lysates yielded 274 significantly deregulated
proteins between controls and Nf1Myf5 (Figure 3A). KEGG
pathway analysis showed enrichment for the categories
‘translation’, ‘carbon metabolism’, and ‘ribosome’ amongst
proteins down‐regulated in Nf1Myf5 mutants compared with
controls (Figure 3B). Amongst proteins up‐regulated in
Nf1Myf5 muscle, KEGG terms ‘oxidative phosphorylation’,
‘protein digestion’, ‘proteasome’, ‘PPAR signaling pathway’,
and ‘fatty acid degradation’ were overrepresented
(Figure 3B).
This was confirmed by RNA‐Seq analysis of p21 TA muscle
tissue. Principal component analysis confirmed separate
clustering of control and Nf1Myf5 samples (Supporting
Information, Figure S3B). Transcriptome analysis yielded
1917 differentially expressed genes; 928 genes were
down‐regulated and 989 genes were up‐regulated in Nf1Myf5
muscle relative to controls (Figure 3C). GO as well as KEGG
analysis of transcriptome data highlighted terms as ‘muscle
cell differentiation’, ‘muscle hypertrophy’, ‘carbohydrate me-
tabolism’ or ‘glycolysis/gluconeogenesis’ as overrepresented
in genes down‐regulated in Nf1Myf5 muscle (Figure 3D).
Conversely, terms as ‘oxidation‐reduction process’,
‘mitochondrial electron transport chain’, ‘TCA cycle’, or
‘oxidative phosphorylation’, as well as several terms related
to amino acid catabolism, were enriched in genes
up‐regulated in Nf1Myf5 muscle (Figure 3E). We note that,
although affected biological processes align between prote-
ome and transcriptome analyses, deregulated proteins and
genes [including tricarboxic acid (TCA) cycle and OXPHOS]
are not positively correlated (Supporting Information, Figure
S3C). While under steady‐state conditions mRNA and protein
levels typically correlate, discrepancy is not uncommon for
dynamic situations,32 which we consider the case for our
Nf1Myf5 mutant. We also noted ‘insulin signaling pathway’
enriched in down‐regulated genes; we therefore first
analysed Nf1Myf5 mice for blood glucose levels, which were
unchanged (Supporting Information, Figure S4A). Also, phos-
phorylation of Akt as well as IRS1 in random fed animals
was not significantly changed (Supporting Information, Figure
S4B and S4C). In summary, proteome and transcriptome
analyses suggest (i) metabolic shift and (ii) deranged protein
homeostasis in Nf1Myf5 mice.
Increased oxidative metabolism in Nf1Myf5 muscle
Skeletal muscle primarily gains energy by breakdown of car-
bohydrates and fatty acids, both being able to feed into mito-
chondrial respiration as the most efficient way of ATP
production. In Nf1Myf5 muscle, GO as well as KEGG categories
associated with the TCA cycle or the mitochondrial electron
transport chain were overrepresented in genes and proteins
up‐regulated in Nf1Myf5 muscle (Figure 3B and 3E). GSEA of
the RNA‐Seq data highlighted enrichment of genes associated
with ‘glucose catabolic process’ in control muscle and of
genes associated with ‘oxidative phosphorylation’ in Nf1Myf5
muscle (Figure 4A). We therefore mined the differentially
expressed gene set for genes encoding components of glycol-
ysis or TCA cycle/oxidative phosphorylation, respectively. This
showed that glycolysis appeared globally down‐regulated,
with exception of Pdk2, Pdk4, and Ldhb, while TCA cycle
and OXPHOS genes were globally up‐regulated (Figure 4B
and 4C). In line, detailed analysis of proteome data showed
several proteins of the TCA cycle as well as the electron trans-
port chain up‐regulated in Nf1Myf5 muscle (Figure 4D).
To directly measure mitochondrial oxidative metabolism,
we employed high‐resolution respirometry31 on freshly iso-
lated muscle fibres from 5‐week‐old control and Nf1Myf5
mice. We analysed the EDL muscle as a prototypical preva-
lently fast glycolytic muscle and the soleus muscle as a proto-
typical oxidative muscle for comparison (Figure 4E). First,
non‐phosphorylating leak respiration (= oxygen flux after ad-
dition fibres plus complex I substrates malate and pyruvate,
with no ADP present) was unaffected in soleus and slightly al-
though not significantly increased in EDL muscle of Nf1Myf5
mice. Following the addition of ADP in saturating concentra-
tions and glutamate, another complex I substrate, the
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FIGURE 3 Proteome and transcriptome analyses of postnatal day 21 muscles. (A) Volcano plot of control vs. Nf1Myf5 muscle proteome data. Individual
deregulated proteins are indicated (blue: down‐regulation, red: up‐regulation). (B) KEGG pathway analysis of proteins down‐regulated (top) and pro-
teins up‐regulated in Nf1
Myf5
muscle vs. control. (C) Volcano plot of control vs. Nf1
Myf5
muscle transcriptome data. Individual deregulated transcripts
are indicated (blue: down‐regulation, red: up‐regulation). (D) Gene ontology (GO) and KEGG analysis of transcripts down‐regulated in Nf1Myf5 muscle
vs. control. (E) GO and KEGG analysis of transcripts up‐regulated in Nf1Myf5 muscle vs. control.
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FIGURE 4 Disrupted metabolic homeostasis in Nf1Myf5 muscle. (A) Gene set enrichment analysis (GSEA) of raw control vs. Nf1Myf5 muscle tran-
scriptome data for the terms ‘glucose catabolic process’ and ‘oxidative phosphorylation’. (B) Heat map of differentially expressed glycolytic genes (con-
trol vs. Nf1
Myf5
muscle). (C) Heat map of differentially expressed genes (control vs. Nf1
Myf5
muscle) of tricarboxic acid (TCA) cycle and oxidative
phosphorylation machinery (OXPHOS) components. (D) Depiction of significantly deregulated proteins related to TCA cycle and OXPHOS. Proteome
analysis of p21 muscle, genotypes are indicated. (E) Real‐time high‐resolution respirometry measurement of control vs. Nf1
Myf5
EDL (extensor
digitorum longus) and Sol (soleus) muscles (n = 7 animals for both genotypes). Error bars represent standard error of means. P‐value was calculated
by two‐sided unpaired t‐test.
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oxidative phosphorylation (OXPHOS) state, and subsequently
the maximum coupled respiration through both mitochon-
drial complex I and II (CI&CII, after further addition of succi-
nate) were measured, which were increased in both types
of muscle of Nf1Myf5 mice, although the effects were more
pronounced in soleus of Nf1Myf5 mice. Finally, maximum elec-
tron transfer system capacity (ETSCI&CII, following addition of
the exogenous mitochondrial uncoupler FCCP) confirmed the
increased mitochondrial respiratory capacity in muscles of
Nf1Myf5 animals (Figure 4E).
Glycolytic‐to‐oxidative fibre type shift in Nf1Myf5
muscle
Most muscles of the limbs consist of predominantly
fast‐twitching type 2 fibres, which are larger in diameter than
slow‐twitching type 1 fibres and produce main mechanical
force. Type 2 fibres can be subdivided into type 2B fibres that
show anaerobic glycolytic metabolism and type 2A fibres that
use aerobic metabolism. Type 2B fibres express myosin heavy
chain type 2B (MyHC‐2B) or a combination of MyHC‐2B and
MyHC‐2X (encoded by the Myh4 and Myh1 genes, respec-
tively). Type 2A fibres express MyHC‐2A encoded by Myh2,
and type 1 fibres express MyHC‐1 encoded by Myh7. Mining
the p21 transcriptome data for markers of fast vs. slow
fibres33,34 showed reduction of fast markers and increased
expression of slow markers in Nf1Myf5 muscles
(Figure 5A). Quantitative real‐time PCR (RT‐qPCR) confirmed
up‐regulation of Myh2 and Myh7 and down‐regulation of
Myh4 mRNA in Nf1Myf5 muscle (Figure 5B). In accordance,
protein levels of MyHC‐1 were increased, and levels of
MyHC‐2B were decreased in Nf1Myf5 TA muscles (Figure 5C).
This indicated distorted fast/slow fibre composition in
Nf1Myf5 muscles.
The expression of fast fibre‐related genes is induced in the
first weeks of postnatal life in rodents.15,35 We therefore
analysed the number of type 1 fibres in TA and EDL muscles
(which are predominantly composed of fast fibres) over time
(Figure 5D and 5E). At postnatal day 7 (p7), no differences
were observed. But from postnatal day 14 (p14), a persistent
slight increase in type 1 fibres in the TA muscle and a tran-
sient increase in the EDL muscle in Nf1Myf5 mice during post-
natal development were seen (Figure 5D and 5E). We then
analysed the proportion of type 2A and type 2B fibres in adult
mice, revealing a shift of type 2B/X to type 2A fibres, that is,
towards the fast oxidative phenotype, in Nf1Myf5 mice (Figure
5F and 5G). Of note, Nf1 was not differentially expressed in
wild‐type soleus (predominantly type 1 and 2A fibres) or TA
(predominantly type 2b/X fibres) muscles (Figure 5H). We
conclude that Nf1Myf5 muscles show a metabolic shift to-
wards oxidative metabolism with partial conversion of type
2B/X to type 2A or type 1 fibres.
Defective protein homeostasis in Nf1‐deficient
muscles
Proteome analysis showed a significant down‐regulation of
several components of the translational machinery, especially
ribosomal proteins as well as tRNA synthases (Figures 3A and
6A). Conversely, several proteasomal subunits were
up‐regulated (Figures 3A and 6B). This may indicate de-
creased protein synthesis and increased breakdown suggest-
ing a mechanism paralleling myofibre atrophy. In line,
RT‐qPCR analysis demonstrated up‐regulation of common
atrophy‐related transcripts36–38 in Nf1Myf5 muscle (Figure
6C). These genes comprise Ctsl (cathepsin L) and Psma1
(proteasomal subunit alpha 1), or the classical atrogenes
Fbxo32 (atrogin‐1/MAFbx) and Trim63 (MuRF1).39 Myofibre
atrophy typically is caused by a dysbalance between protein
synthesis and breakdown. Protein synthesis in skeletal muscle
is mainly regulated via mTORC1.13,14 Interestingly, the KEGG
term ‘mTOR signaling pathway’ was enriched in genes
down‐regulated in Nf1Myf5 muscle (Figure 3D). To analyse
mTORC1 activity, we assessed phosphorylation of mTOR as
well as the mTORC1 downstream target S6 ribosomal protein.
p21 Nf1Myf5 muscle tissue showed hallmarks of decreased
mTORC1 signalling, with decreased phosphorylation of mTOR
Ser2448 and decreased S6 Ser235/236 phosphorylation (Fig-
ure 6D). Altogether, this suggests disturbed protein homeo-
stasis in Nf1Myf5 muscle with decreased mTORC1‐driven
protein synthesis and increased protein breakdown. Such al-
terations may be the result of a muscular energy deficit.13
In line, Nf1Myf5 muscle showed increased levels of phosphor-
ylated AMP‐dependent kinase (AMPK), the most prominent
intracellular energy sensor (Figure 6E). In sum, Nf1Myf5 ani-
mals show typical signs of muscle atrophy with decreased an-
abolic signalling, in combination with an unmet energy
demand.
Increased fatty acid catabolism in Nf1Myf5 muscle
Increased oxidative metabolism, but concomitant
down‐regulation of glycolytic genes, indicated that Nf1Myf5
muscles may predominantly use fatty acids to feed the
TCA cycle. Analysis of proteome as well as transcriptome
data highlighted terms associated with fatty acid catabo-
lism, as ‘fatty acid degradation’ (proteome) or ‘fatty acid
beta‐oxidation’ (transcriptome) were significantly enriched
amongst proteins/mRNAs up‐regulated in Nf1Myf5 muscle
(Figure 3B and 3E). Accordingly, several proteins associated
with cellular lipid uptake and breakdown were up‐regulated
in Nf1Myf5 muscle (Figure 7A). In line with GO and KEGG
analysis of differentially expressed genes, GSEA of tran-
scriptome data showed genes belonging to the clusters
‘fatty acid beta‐oxidation’ and ‘fatty acid catabolic process’
strongly enriched in Nf1Myf5 muscle (Figure 7B). Indeed,
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FIGURE 5 Fibre type shift in Nf1Myf5 muscle. (A) Heat maps showing differentially expressed genes specific for fast or slow/intermediate fibres, respec-
tively, between control and Nf1Myf5 muscle. (B) RT‐qPCR analysis of myosin heavy chain genes Myh7, Myh2, and Myh4 on control vs. Nf1Myf5 muscle
(n = 3 animals per genotype). (C) Western blot analysis of myosin heavy chain type 1 (MyHC‐1) and type 2B (MyHC‐2B) on control vs. Nf1
Myf5
muscle.
Quantification below (n = 3 animals per genotype). (D) Immunolabelling for MyHC‐1 on cross sections of p21 control vs. Nf1Myf5 lower legs. TA muscles
are shown as magnifications right. Sections are stained for laminin and DAPI. (E) Quantification of type 1 fibres/all fibres for indicated postnatal time
points on TA and EDL muscles (n = 3 animals per genotype). (F) Immunolabelling for fast oxidative fibre type myosin (MyHC‐2A) and MyHC‐1 on cross
sections of control vs. Nf1Myf5 lower legs. Sections are stained for laminin and DAPI. EDL muscles are shown as magnifications right. (G) Quantification
of percentage of MyHC‐2A fibres/all fibres (n = 3 animals per genotype). (H) RT‐qPCR analysis of Nf1 expression between wild‐type p21 TA and Sol
muscles. Error bars represent standard error of means. P‐value was calculated by two‐sided unpaired t‐test.
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numerous genes belonging to the GO term ‘fatty acid me-
tabolism’ were up‐regulated in Nf1Myf5 muscle (Figure 7C),
including the gene encoding the main fatty acid transporter
Cd36, or several acyl‐CoA dehydrogenases, which not only
play a role in β‐oxidation but also breakdown of branched
amino acids. Up‐regulation of several genes of this panel
in Nf1Myf5 muscle (Lpl encoding part of the enzyme com-
plex responsible for lipid uptake, fatty acid binding proteins
FIGURE 6 Disturbed protein homeostasis and energy deficit in Nf1Myf5 muscle. (A) Depiction of significantly deregulated components of the ribosome
and proteins related to translation. Proteome analysis of p21 muscle, genotypes are indicated. (B) Depiction of significantly deregulated proteins re-
lated to the KEGG term ‘protein digestion’. Proteome analysis of p21 muscle, genotypes are indicated. (C) RT‐qPCR analysis of p21 control and Nf1Myf5
muscle for transcripts related to muscle atrophy (n = 3 animals per genotype). (D) Western blot analysis for phosphorylated mTOR (Ser2448) and phos-
phorylated S6 ribosomal protein (Ser235/236). Quantification shown right (n = 3 animals per genotype). (E) Western blot analysis for phosphorylated
AMPK (Thr172). Quantification shown right (n = 4 animals per genotype). Error bars represent standard error of means. P‐value was calculated by
two‐sided unpaired t‐test.
Cell autonomous requirement of Nf1 in muscle 13
Journal of Cachexia, Sarcopenia and Muscle 2020
DOI: 10.1002/jcsm.12632
Fabp3 and Fabp4, carnitine palmitoyltransferases Cpt1b and
Cpt2, and Acad1 encoding medium chain acyl‐CoA dehydro-
genase) was confirmed by RT‐qPCR (Figure 7D). In sum,
proteome as well as transcriptome data indicate increased
fatty acid breakdown in Nf1Myf5 muscle to fuel the TCA
cycle and OXPHOS. As opposed to Nf1Prx1 mice, we did
not observe increased muscle interstitial adipose tissue
(Figure 7E). Contrasting previous reports,22 we did not
find indication of ectopic lipid storage in muscle fibres
in our muscle‐specific Nf1 mutants at 1 or 12 weeks of
age (Figure 7E; Supporting Information, Figure S5A
and S5B).
PPARγ has been involved in promoting intramuscular
lipolysis.40,41 In muscle tissue of Nf1Myf5 mice, we found over-
expression of Pparg mRNA (Figure 7F); specific up‐regulation
of PPARγ isoform 1 was confirmed on the protein level in 7‐
week‐old and also already in 2‐week‐old animals (Figure
7G). In line, GSEA showed enrichment for ‘adipogenic targets
of PPARG’ enriched in Nf1 mutants (Figure 7H). Similarly,
‘PPAR signaling pathway’ was enriched in transcripts and
FIGURE 7 Increased fatty acid oxidation in Nf1Myf5 muscle. (A) Depiction of significantly deregulated proteins related to cellular lipid uptake and break-
down. Proteome analysis of p21 muscle, genotypes are indicated. (B) Gene set enrichment analysis (GSEA) of control vs. Nf1
Myf5
muscle transcriptome
data for the terms ‘fatty acid beta‐oxidation’ and ‘fatty acid catabolic process’. (C) Heat map of differentially expressed genes related to fatty acid me-
tabolism (control vs. Nf1
Myf5
muscle). (D) RT‐qPCR analysis in control vs. Nf1
Myf5
muscle of selected genes related to fatty acid uptake, transport, and
catabolism (n = 3 animals per genotype). (E) Perilipin (PLIN, red) and MyHC (green) immunolabelling on 12‐week‐old control vs. Nf1Myf5 muscle. Over-
view tile scan images left, magnifications showing subcutaneous adipose tissue and adjacent muscle tissue shown right. (F) RT‐qPCR analysis of Pparg
in control vs. Nf1
Myf5
muscle (n = 3 animals per genotype). (G) Western blot analysis for PPARγ on control vs. Nf1Myf5 muscle. (H) GSEA of control vs.
Nf1Myf5 muscle transcriptome data for the term ‘adipogenic targets of PPARG’. (I) RT‐qPCR analysis for Adipoq, Il6, and Fgf21 on control vs. Nf1Myf5
muscle (n = 3 animals per genotype). Error bars represent standard error of means. P‐value was calculated by two‐sided unpaired t‐test.
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proteins up‐regulated in Nf1 mutants (Figure 3B and 3E).
PPARγ was shown to induce the myokine adiponectin
(Adipoq).42 Nf1‐deficient muscle showed increased expres-
sion of Adipoq as well as mRNAs of the myokine Il6 and the
catabolic cytokine Fgf21 (Figure 7I).
Paucity of white adipose tissue in Nf1Myf5 mice
Finally, increased fatty acid consumption in Nf1Myf5 muscles
as indicated by proteome and transcriptome analyses sug-
gests increased lipid mobilization from adipose tissue. Indeed,
Nf1Myf5 animals showed a drastic reduction of their white
adipose tissue (WAT), affecting both subcutaneous and vis-
ceral WATs (Figure 8A and 8B). This was specific to WAT;
brown adipose tissue (BAT) depots were unaffected (Figure
8B). In histology, WAT appeared denser, deprived of lipid
content (Figure 8C). In line, RT‐qPCR analysis showed mild in-
duction of Lipe encoding hormone‐sensitive lipase (Figure
8D), and strong induction of Pnpla2 encoding adipose triglyc-
eride lipase (ATGL), the rate‐limiting enzyme of lipolysis (Fig-
ure 8D). Dgat2 encoding diacylglycerol O‐acyltransferase 2,
the rate‐limiting enzyme of lipogenesis, was not significantly
induced (Figure 8D). Decreased expression of Lpl and Cd36
in WAT of Nf1Myf5 mice (Figure 8D; Supporting Information,
Figure S6A) suggests decreased lipid uptake, and decreased
FIGURE 8 Paucity of white adipose tissue in Nf1Myf5 mice. (A) Nf1Myf5 (p21) mice show reduced posterior subcutaneous white adipose tissue (WAT).
Note dark red appearance of muscles in Nf1+ mutant. (B) Weight of adipose tissue depots of control vs. Nf1Myf5 mice at 12 weeks of age. Adipose depot
weight was normalized to body weight. AsWAT, anterior subcutaneous white adipose tissue; psWAT, posterior subcutaneous white adipose tissue;
rWAT, retroperitoneal white adipose tissue; iBAT, interscapular brown adipose tissue; sBAT, subscapular brown adipose tissue; cBAT, cervical brown
adipose tissue (n = 4 animals per genotype). (C) Histological analysis (haematoxylin and eosin) of p21 psWAT of control vs. Nf1
Myf5
mice. (D)
RT‐qPCR analysis of p21 psWAT of control vs. Nf1Myf5 mice for Lipe, Pnpla2, Dgat2, Lpl, and Ucp1 (n = 3 animals per genotype). Error bars represent
standard error of means. P‐value was calculated by two‐sided unpaired t‐test.
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expression of Plin1 confirms decreased lipid storage
(Supporting Information, Figure S6A). Ucp1 was not induced
but rather down‐regulated in Nf1Myf5 WAT (Figure 8D), sug-
gesting no ‘browning’ of WAT. Expression of Pparg was unal-
tered in Nf1Myf5 posterior subcutaneous WAT, as were mtCo1
and Cs (encoding mitochondrial cytochrome c oxidase and cit-
rate synthase, respectively) as representatives of electron
transport chain and TCA cycle (Supporting Information, Fig-
ure S6A). BAT originates in large part from a dermomyotomal
Myf5+ progenitor population43; thus, Nf1 inactivation in BAT
may influence the phenotype. Intriguingly, RT‐qPCR analysis
of BAT showed some overlap in gene deregulation with
Nf1‐deficient muscle, as mtCo1 was up‐regulated; however,
Cs, Pparg, and also Ucp1 were unaltered (Supporting Infor-
mation, Figure S6B) suggesting no major influence on BAT.
This altogether suggests a general catabolic state of Nf1Myf5
animals forced by unmet energetic need of muscle tissue
leading to a cachectic state with increased lipid mobilization.
Discussion
We show here that Nf1 inactivation specifically in the myo-
genic lineage leads to postnatal myopathy mirroring a key
feature seen in Nf1 patients. Thus, the Nf1Myf5 line enables
analysis of Nf1 function in postnatal muscles and in compari-
son with models as the Nf1Prx1 mouse is suitable to distin-
guish muscle specific from non‐myogenic functions of Nf1.
Nf1Myf5 mice are viable, while Nf1Lbx1 (this study) and
Nf1MyoD mice22 were postnatally lethal. This difference may
be caused by different efficacy of the Cre driver lines used.
Lbx1Cre efficiently targets early migrating myogenic progeni-
tors, including those of the diaphragm and tongue,24 and ex-
pression of Lbx1 precedes the expression of Myf5.44 While
MyoD is expressed in all myogenic cells, not all myoblasts
have experienced expression of Myf5, although there is dis-
pute whether Myf5 and MyoD cells represent partially sepa-
rate lineages.45–48 Thus, very likely not all myogenic cells
are targeted in the Nf1Myf5 model, possibly alleviating the
phenotype to a life‐compatible level. Depletion of the Myf5
lineage led to compensatory takeover by MyoD‐lineage
cells,45 and Comai et al.46 demonstrated a marked compensa-
tory effect of recombination escapers upon Myf5 cell deple-
tion. Importantly, robust knockdown of Nf1 mRNA in
Nf1Myf5 mice at p21 argues against a possible lineage take-
over of Myf5‐negative cells or of recombination escapers,
suggesting that no significant skewing of the myogenic line-
age had occurred in our model.
Nf1Myf5 mice did not show increased interstitial fibrotic
and adipogenic infiltration of muscle as it was seen after inac-
tivation of Nf1 in limb mesenchyme via Prx1Cre.19 Muscle in-
terstitial fibroblasts and adipocytes do not originate from
myogenic cells but from non‐myogenic mesenchymal
progenitors, the so‐called fibro‐adipogenic progenitors.49–51
These cells in turn derive from lateral plate
mesoderm‐derived limb bud mesenchyme.52 The same devel-
opmental mesenchymal progenitors also form muscle inter-
stitial fibroblasts and adipocytes during development.53
Prx1Cre targets the entire limb mesenchyme21 encompassing
this mesenchymal progenitor population during
development.54 Thus, comparing Nf1Prx1 and Nf1Myf5 models,
we conclude that fibro‐fatty infiltration of muscle in the NF1-
Prx1 model does not originate from myogenic cells but from interstitial mesen-
chymal cells. However, in another model of muscle‐specific inactivation of Nf1
(MyoDCre), ectopic intramyocellular lipid accumulation was
reported,22 which we did not observe in our model. This dis-
crepancy might be caused by the different Cre drivers used;
of note, MyoDCre was reported to be active in the developing
liver55; thus, an indirect effect may not be excluded.
Nf1Myf5 mice show reduced postnatal fibre growth that
manifested early in life. This suggests that loss of Nf1 does
not induce muscle atrophy at a specific time point but rather
that NF1‐associated muscle weakness is a continuous process
of decreased hypertrophic growth beginning in childhood. In-
deed, muscle weakness and decreased muscle cross‐sectional
area are already seen in paediatric patients.7,8 This strongly
suggests that muscular manifestations in NF1 are predomi-
nantly a developmental disorder and any treatment towards
an amelioration of the muscular phenotype would have to
encompass this critical phase. In line with this, a recent study
showed that treatment of Prx1Cre;Nf1flox/flox mice with the
MEK inhibitor PD0325901 starting at 4 weeks after birth did
not result in appreciable amelioration of the muscular
phenotype.56 In Nf1Myf5 mice, predominantly fast (type 2)
fibres are affected. In general, type 2 fibres have higher
potential for hypertrophy than type 1 fibres, which also
makes them more vulnerable for atrophy.57 Nevertheless, dif-
ferent myopathies predominantly affect different fibre types;
the underlying cause is mostly unclear.16 Our results indicate
dysbalanced protein homeostasis in Nf1Myf5 muscle. TORC1
signalling is a master regulator for protein synthesis.13,14
Nf1Myf5 muscle showed reduced mTORC1 activation that is
in line with proteome and transcriptome data, altogether in-
dicating decreased capacity for protein synthesis. This may
also contribute to the divergence of our proteome and tran-
scriptome datasets. On the other hand, common atrogenes
were up‐regulated on the transcript level, and proteasomal
components were up‐regulated on transcript and protein
levels, in addition suggesting increased protein breakdown.
Thus, Nf1‐associated muscle atrophy appears to overlap gen-
eral mechanisms observed in other atrophy conditions includ-
ing myopathies, sarcopenia, and cachexia, that is, excessive
protein breakdown and decreased protein synthesis.13
In parallel, we observed a fibre type shift from glycolytic
type 2 fibres to oxidative type 2 and in part to type 1 fibres.
In adult Nf1Prx1 mice, no fibre type shift was reported20; how-
ever, this had not been quantified. During embryonic and
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foetal myogenesis, muscle fibres predominantly show oxida-
tive type gene and protein expression. Fast‐type gene and
protein expression is first detected during late foetal develop-
ment; the major slow‐to‐fast fibre type change occurs during
the early postnatal period.15 The emergence of different fibre
types in development is under control of transcription factors
such as Six1, Six4, Sox6, Tbx15, Prdm1 (aka Blimp1), and
Nfix58–64; however, we did not detect a significant deregula-
tion of these factors in our transcriptome data (Supporting In-
formation, Data S1). Mature fibres have a degree of plasticity
and can shift their metabolism based on, for example, endur-
ance vs. peak force training.15 Importantly, fibre type shifts
are involved in muscular disorders and muscle aging.15,16
Nf1 is best known as a Ras‐GTPase‐activating protein that
negatively regulates downstream MEK–ERK signalling.1 Inter-
estingly, ERK1/2 activity itself was involved in regulating mus-
cle fibre types previously.15 In line, it was recently shown that
expression of an activated form of MEK1 in muscle fibres can
drive a metabolic shift to oxidative fibres.65
In line with increased oxidative metabolism relying on fatty
acid consumption, Nf1Myf5 mice showed severe reduction of
WAT. Strong induction of lipolytic enzymes (HSL and ATGL),
but no significant induction of lipogenic enzyme DGAT2, sug-
gests an overweight of lipolysis over lipogenesis. In line, re-
duced Plin1 levels were associated with increased lipolysis.66
Increased lipid mobilization leading to loss of adipose tissue
is a hallmark of cancer cachexia. As in our model, this is fre-
quently attributed to increased lipolysis associated with
up‐regulation of ATGL expression.66 Myf5Cre‐mediated gene
inactivation preferentially targets the myogenic lineage; how-
ever, it also targets BAT as well as several (anteriorly located)
WAT depots.67 Thus, inactivation of Nf1 in subsets of adipo-
cyte progenitors may have a direct effect on
adipogenesis/adipocyte function. Inactivation of the tumour
suppressor Pten, leading to hyperactivation of the PI3K path-
way, in the Myf5 lineage led to increased size of anterior BAT
and WAT depots, while posterior WAT depots were virtually
absent in mutants.68 We did not detect differences in BAT
size in Nf1Myf5 mice. Moreover, Ucp1 mRNA was not
up‐regulated in BAT, indicating that Nf1‐deficient BAT does
not show increased energy expenditure. WAT depots were
reduced irrespective of anatomical location; anterior subcuta-
neous WAT and retroperitoneal WAT that are targeted by
Myf5Cre, as well as posterior subcutaneous WAT that is not
targeted,67 were strongly affected. This argues against a cell
autonomous effect on Nf1 deletion in adipogenic
progenitors/adipocytes, but rather in favour of a
muscle‐derived effect enforcing lipolysis in WAT.
We observed up‐regulation of mRNAs encoding myokines,
that is, muscle‐produced endocrine signalling factors. FGF21
and IL6 were shown to stimulate lipolysis in WAT.69,70 IL6 also
stimulates lipolysis and fatty acid oxidation in muscle in an
autocrine fashion, interestingly via AMPK activation.71–73 Fur-
thermore, Adipoq, encoding adiponectin, was induced.
Adiponectin is mainly known as an adipokine; however, also
skeletal muscle produces adiponectin, and Adipoq knockout
mice show increased intramyocellular lipid content.74
Adiponectin expression in muscle can be induced by PPARγ,42
which was overexpressed in Nf1Myf5 muscle. PPARγ in muscle
promotes fatty acid oxidation.40,41 PPARγ overexpression in
muscle protects from obesity‐induced diabetes, leads to in-
creased adiponectin expression, and induces oxidative me-
tabolism, and muscles have reduced lipid content.42
Conversely, muscle‐specific inactivation of PPARγ induces
obesity and insulin resistance.75,76 FGF21 is well described
as mitochondrial stress‐induced myokine.77–79 Very recently,
FGF21 was described as a novel player in the regulation of
muscle mass during fasting‐induced muscle atrophy and
weakness.80 Here, we describe a strong induction of muscle
Fgf21 in response to genetic ablation of Nf1, together with
a dramatic reduction of WAT depots, affecting both subcuta-
neous and visceral WATs. However, future studies are war-
ranted to clarify the protective or detrimental catabolic
action of FGF21 via inter‐tissue crosstalk in Nf1Myf5 animals.
Contrasting increased oxidative metabolism and fatty acid
breakdown, down‐regulation of all glycolysis components in
the transcriptome analysis indicated decreased glycolytic flux
in Nf1Myf5 muscles. Intriguingly, Pdk2, Pdk4, and Ldhb were
up‐regulated. The B‐isoform of LDH is mainly expressed in ox-
idative muscle, and overexpression of Ldhb increases oxida-
tive metabolism81 in line with the oxidative phenotype we
observe. PDK2 and PDK4 negatively regulate pyruvate dehy-
drogenase and thus impair funnelling pyruvate from glycolysis
towards usage in the TCA cycle, shunting mitochondrial me-
tabolism towards fatty acid usage.15 This altogether suggests
that utilization of glucose as fuel for the TCA cycle is impaired
in Nf1Myf5 muscle; thus, fatty acids as alternative energy
source need to be used. Intriguingly, a decreased respiratory
quotient indicating lower carbohydrate and increased lipid ox-
idation was demonstrated in NF1 patients.82 Thus, defective
glycolysis may therefore explain why Nf1Myf5 muscles shift to-
wards oxidative metabolism and primarily rely on fatty acids
but could also contribute to the apparent energy deficit of
Nf1‐deficient muscle indicated by AMPK activation. Nf1 is well
known as a tumour suppressor gene repressing RAS signalling.
Increased RAS signalling or loss of Nf1 is typically associated
with the induction of a Warburg effect, that is, increased gly-
colytic flux under aerobic conditions, as well as the induction
of pathways supporting cell growth, as mTORC1.83,84Why loss
of Nf1 in myogenic cells leads to effectively opposite outcome
is unknown; however, it indicates differences in either the cel-
lular environment or intracellular signal reception that lead to
a different interpretation of Nf1‐dependent signals. De-
creased energy charge is sensed in cells via AMPK that is a
master regulator of cellular energy homeostasis.85 Activation
of AMPK can reduce mTORC1 activity and thus protein synthe-
sis, providing a possible explanation for the reduced hypertro-
phic growth of Nf1Myf5 muscles. In turn, AMPK activation is
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known to induce mitochondrial biogenesis, glucose uptake,
and fatty acid consumption.85,86 This altogether suggests that
impaired glycolysis may be the primary defect in Nf1Myf5 mus-
cle, leading to an energy deficit, shifting cellular metabolism
via AMPK towards OXPHOS.
Mitochondria are described as the predominant source of
reactive oxidant species (ROS) in muscle fibres.87 Notably, ox-
idative stress in skeletal muscles can promote protein
synthesis/degradation imbalance and muscle wasting.88 In-
creased ROS levels in cachectic muscle could be attributed
to the reduction in the activity of endogenous antioxidant
enzymes.89 In drosophila, loss of Nf1 caused mitochondrial ox-
idative stress concomitant to decreased ATP production.90 GO
and KEGG analysis of transcriptome data showed enrichment
of the terms ‘response to oxygen‐containing compound’, ‘re-
sponse to oxidative stress’, ‘reactive oxygen species metabolic
process’, ‘response to reactive oxygen species (GO)’, and ‘glu-
tathione metabolism’ (KEGG) in genes up‐regulated in Nf1Myf5
muscle (Figure 3E). In addition, transcriptome analysis showed
increased expression of NADPH oxidase genes Cybb (Nox2)
and Nox4 (Supporting Information, Data S1), which are an ad-
ditional source of ROS.91 This indicates that increased mito-
chondrial respiration in Nf1Myf5 muscle may lead to oxidative
stress, hampering mitochondrial energy production. This
raises the question whether a concomitant increased mito-
chondrial ROS production may even aggravate the situation
in Nf1Myf5 mice, potentially causing a vicious cycle.
In summary, Nf1Myf5 represents a viable mouse model for
muscle‐specific inactivation of Nf1 that recapitulates the pae-
diatric myopathy seen in NF1 patients. Nf1 deficiency disrupts
metabolic homeostasis in muscle leading to muscular energy
deficit and a catabolic state causing reduced postnatal muscle
hypertrophy. As postnatal muscle growth is carried by a com-
bination of cell accrual and protein synthesis,11,12 Nf1 defi-
ciency may also alter behaviour of Myf5+ myogenic
progenitors, which should be addressed in future studies
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Figure S1 Characterization of Lbx1Cre and Myf5Cre specificity
(A, B) Analysis of Lbx1Cre and Myf5Cre specificity. Cre mice
were bred to Rosa26mTmG reporter mice and analyzed at
embryonic day 18 (E18.5; A) or postnatal day 21 (p21; B). Stain-
ing: green depicts mG reporter activity tracing recombined
cells, red depicts mT reporter activity tracing
non‐recombined cells. Satellite cells have been stained for
Pax7, neurons for β‐tubulin III (purple). TB: Triceps brachii;
CT: connective tissue; EDL: Extensor digitorum longus; TA:
Tibialis anterior.
Figure S2 Extended data for pre‐ and postnatal characteriza-
tion of Nf1Myf5 animals (A) Whole‐mount in‐situ hybridiza-
tion of 14 day old control and Nf1Myf5 embryos for Myod.
Quantification of Myod+ area in limbs is shown right (n=3 an-
imals per genotype). (B) RT‐qPCR analysis of Nf1 expression in
p21 Tibialis anterior (TA) muscles of Nf1+/+, Myf5Cre;Nf1flox/+
and Myf5Cre;Nf1flox/flox animals (n=3 animals per genotype).
(C) RT‐qPCR analysis of Myf5 expression from Myf5+/+;
Nf1flox/+ vs. Myf5Cre/+;Nf1flox/flox animals in E18.5 limb
muscles and p21 TA muscle (n=3 animals per genotype). (D)
Quantification of total myofiber numbers in muscles (TB: Tri-
ceps brachii, TA: Tibialis anterior, EDL: Extensor digitorum
longus) of p21 control and Nf1Myf5 animals (n=3 animals
per genotype). Error bars represent standard error of means
(SEM). P‐value was calculated by two‐sided unpaired t‐test.
P‐value above 0,05 was considered not significant (N.S.).
Figure S3 Extended data proteome and transcriptome analy-
sis (A, B) Principal component analysis (PCA) of proteome
(A) and transcriptome (B) data. Genotypes are indicated. (C)
Correlation analysis of transcriptome and proteome data.
The Pearson correlation coefficient between transcript and
protein levels of Nf1Myf5 and control TA muscles are shown
as a log2‐fold change (all squares, ‐0.144). Specific factors
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involved in the ETC (red, ‐0.0796) and the TCA cycle (green, ‐
0.595) are highlighted. Pathway identities were retrieved
from KEGG.
Figure S4 Blood glucose and insulin signaling in Nf1Myf5 mice
(A) Blood glucose test in 5 weeks old Nf1Myf5 animals (n=7
animals per genotype; each dot represents measurement
from one individual animal). (B) Western blot analysis for
phosphorylated AKT (Ser473) and phosphorylated IRS1
(Ser1101, Ser 636/639). (C) Quantification of p‐AKT(s473), p‐
IRS1(s1101) and p‐IRS1(s636/639) relative to β‐actin levels
(top); bottom: β‐actin was equally abundant in control and
Nf1Myf5 samples, measured relative to Ponceau S staining
(n=3 animals per genotype). Error bars represent standard er-
ror of means (SEM). P‐value was calculated by two‐sided un-
paired t‐test.
Figure S5 Extended data for lipid metabolism in Nf1Myf5 mus-
cle (A) Hind limb cross sections of 1 week (top) and 12 week
(bottom) control and Nf1Myf5 mice stained for Oil red O
(ORO) and hematoxylin. Oil red O positive muscle‐adjacent
adipocytes can be seen, frequently lipids smear into the mus-
cle area close to these sites. However the majority of muscle
tissue is free of ectopic lipid staining in control and in Nf1Myf5
mice (see inserts). (B) Images of hind limb cross sections of
1 week (top) and 12 week (bottom) control and Nf1Myf5 mice
stained for Oil red O (ORO) and DAPI imaged with DIC optics.
Top row in each panel shows muscle, bottom row shows sub-
cutaneous adipose tissue and adjacent muscle, where lipid
droplet artefacts due to smearing can be observed.
Figure S6 Extended data for analysis of adipose tissue in
Nf1Myf5 mice (A) RT‐qPCR analysis of psWAT of of 12 week
old control vs. Nf1Myf5 mice for Cd36, Plin1, Pparg, mtCO1
and Cs (n=3 animals per genotype). (B) RT‐qPCR analysis of
interscapular brown adipose tissue (iBAT) of 12 week old con-
trol and Nf1Myf5 animals for mtCO1, Ucp1, Cs and Pparg
mRNA (n=3 animals per genotype). Error bars represent stan-
dard error of means (SEM). P‐value was calculated by
two‐sided unpaired t‐test.
Data S1. Supporting Information (DESeq2 analysis of tran-
scriptome data)
Data S2. Supporting Information (MaxQuant processed out-
put files)
Data S3. Supporting Information (Differentially expressed
proteins)
Table S1. Supporting Information (List of primers)
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